New York, NY -- (SBWIRE) -- 01/10/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: United Microelectronics Corp (ADR) (NYSE:UMC), Merge Healthcare Inc (NASDAQ:MRGE), BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX), Progenics Pharmaceuticals, Inc (NASDAQ:PGNX)
United Microelectronics Corp (ADR) (NYSE:UMC) showed a volume of 1.85million shares by the end of last trade whereas the average volume of the stock remained 1.08 million shares. The stock opened the session at $2.11 but then moved to $2.10. At that price, the stock showed a negative performance of -2.33%. United Microelectronics Corp. is principally engaged in the manufacturing of semiconductor products. The Company operates its businesses primarily through wafer production services. The Company provides the customer-tailored design, testing and production of silicon intellectual property (IP) products, embedded integrated circuits (ICs), masks and wafers.
Will UMC Get Buyers Even After The Recent Rally? Find Out Here
Merge Healthcare Inc (NASDAQ:MRGE) opened the session at $2.29 and closed the session at $2.11. The stock showed a negative performance of -8.66% in previous trading session. Traded with volume of 1.84 million shares in the prior session and the average volume of the stock remained 439,336.00 shares. Merge Healthcare Incorporated (Merge) develops software solutions that facilitate the sharing of images to create an electronic healthcare experience for patients and physicians. Its solutions are designed to help solve some of the challenges in health information exchange, such as the incorporation of medical images and diagnostic information into broader health information technology (IT) applications and the interoperability of software solutions.
Has MRGE Found The Bottom And Ready To Gain Momentum? Find Out Here
BioCryst Pharmaceuticals, Inc (NASDAQ:BCRX) opened the session at $9.51 and closed the session at $9.90. The stock showed a positive performance of 5.32% in previous trading session. beta of the stock remained 3.03. BioCryst Pharmaceuticals, Inc. (BioCryst) is a biotechnology company. BioCryst designs, optimizes and develops drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on therapeutic areas. Peramivir is its product, which is a neuraminidase inhibitor for the treatment of patients with influenza.
Why Should Investors Buy BCRX After The Recent Gain? Just Go Here and Find Out
Progenics Pharmaceuticals, Inc (NASDAQ:PGNX) the stock decreased -1.14% and finished the session at $6.06. Traded with volume of 1.82 million shares in the prior session and the average volume of the stock remained 980,754.00 shares. The beta of the stock remained 1.24. Progenics Pharmaceuticals, Inc. (Progenics) is a biopharmaceutical company focuses on research and development for biotechnology product candidates in oncology, virology, supportive care and gastroenterology. It is also engaged in research to identify multiplex phosphoinositide 3-kinase inhibitors for blocking signaling pathways in the growth of aggressive cancers.
Will PGNX Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)